EAM Global Investors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

EAM Global Investors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-5,177	Closed	-$747K	–	159
2020 Q1	$747K	Buy	5,177 +652	+14%	+$126K	0.44%	93
2019 Q4	$925K	Sell	4,525 -7,302	-62%	-$1.33M	0.37%	108
2019 Q3	$950K	Sell	11,827 -10,030	-46%	-$851K	0.46%	99
2019 Q2	$2.06M	Sell	21,857 -5,198	-19%	-$449K	0.88%	32
2019 Q1	$2.31M	Buy	27,055 +3,488	+15%	+$290K	1.02%	19
2018 Q4	$1.32M	Sell	23,567 -3,954	-14%	-$241K	0.72%	71
2018 Q3	$2.25M	Buy	+27,521	New	+$1.94M	0.91%	19

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM Global Investors's RETA Position: Q2 2020 in Review

EAM Global Investors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2020, closing a stake of 5,177 shares — an estimated $747K sold.

EAM Global Investors first reported a position in RETA in Q3 2018 and held it in 7 quarters. The position peaked at $2.31M in Q1 2019. 207 funds tracked by Wall St. Rank hold RETA as of Q2 2020.

EAM Global Investors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2020 after selling out during the quarter.
EAM Global Investors sold 5,177 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2020, an estimated $747K.
EAM Global Investors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2018 and held it in 7 quarters.
EAM Global Investors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.31M in Q1 2019.
207 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2020.

Based on EAM Global Investors's 13F filing for Q2 2020, filed 13 Aug 2020.